Maharashtra FDA directive against sale, use & distribution of cough syrup

The authority is currently coordinating with Tamil Nadu Drug Control Administration to trace the distribution of the syrup

By: Express News Service

Mumbai | October 6, 2025 11:32 PM IST

2 min read

FDA officials said they are coordinating with the Tamil Nadu Drugs Control Administration to trace the distribution of the affected batch in Maharashtra (File Photo)

The Maharashtra Food and Drugs Administration (FDA) on Monday asked the public and licence holders to immediately stop the sale, distribution or use of Coldrif Syrup (Batch No. SR-13), following reports of child deaths in Madhya Pradesh and Rajasthan allegedly linked to the medicine.

The authority is currently coordinating with Tamil Nadu Drug Control Administration to trace the distribution of the syrup.

“The public is urged to remain cautious and to report any possession of Coldrif Syrup Batch No. SR-13 to the nearest Drugs Control Authority without delay,” the FDA said in a statement. The department warned that the batch, manufactured in May 2025 and expiring in April 2027, is suspected to be adulterated with Diethylene Glycol (DEG), a toxic chemical.

Also Read | Goa bans cough syrup linked to deaths of 11 children in Madhya Pradesh

The statement said that the syrup, containing Phenylephrine Hydrochloride and Chlorpheniramine Maleate, was produced by Sresan Pharma at Sunguvarchathiram in Tamil Nadu’s Kancheepuram district.

FDA officials said they are coordinating with the Tamil Nadu Drugs Control Administration to trace the distribution of the affected batch in Maharashtra. All drugs inspectors and assistant commissioners have been directed to alert retailers, wholesalers and hospitals to immediately freeze any available stock.

The FDA Maharashtra said it is taking all necessary measures to safeguard public health and prevent any further risk to life.

From the homepage